GovChime
Notice ID: 527654d21e7347bfbf716c7897da075dPresolicitation

CellGenix USA/ Various CellGenix cytokines for X-SCID.

Archived on August 25, 2021. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
2:00 PM UTC−04:00
Posted
July 26, 2021
Notice type
Presolicitation
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH - CC
Last updated
Dec 4, 2025

Identifiers

Solicitation number
21-011080
Notice ID
527654d21e7347bfbf716c7897da075d

Description

INTRODUCTION This is not a request for a quotation. A solicitation document will not be issued and quotations will not be requested. THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH), Clinical Center (CC), Office of Purchasing and Contracts (OPC) on behalf of the Center for Cellular Engineering (CCE), Clinical Center (CC) at the National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (including brand-name) to: CELLGENIX USA 1 Nh AVE Portsmouth, NH 03801-2904 United States NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 325413 with a Size Standard 1250. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2021-05 March 10, 2021. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold. STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. GENERAL INFORMATION 1. Title: CellGenix USA/ Various CellGenix cytokines for X-SCID. 2. Background Information: The Center Cellular Engineering (CCE) is an AABB accredited cellular therapy laboratory whose central mission is to provide services to the NIH Institutes to support more than 50 intramural clinical trials. These services include (1) development, evaluation, and validation of investigational new drugs (INDs) for cellular therapies and (2) manufacture of cellular therapy products for approved clinical trials. The majority of these trials are early phase (I/II) trials not intended to result in the development of a commercial product. To provide these services, CCE operates a core facility for the manufacture, storage, and distribution of cellular therapy products. CCE manufactures cellular therapy products from more than 800 collections from patients or healthy donors per year. The products manufactured by the laboratory are used to treat NIH CC patients with cancer, hematological malignancies, marrow failure, genetic immune disorders and autoimmune diseases. All products are manufactured using good manufacturing practices (GMP). The NIH protocols are institutional review board (IRB) approved and in the case of INDs, approval by the US Food and Drug Administration (FDA) for treatment of human subjects. Each subject must consent to participate in a NIH Clinical Research Study. 3. Purpose or Objective: To procure the selected CellGenix Cytokines in the preparation for treatment of patient with X-Linked Severe Deficient Severe Combined Immunodeficiency (X-SCID) enrolled in FDA approved clinical protocols. IND is only allowing cytokines from this manufacturer to be used, prohibit the substitution of any reagent/process named in the original protocol submissions. 4. The Vendor will supply reagents as needed in a timely manner no later than 9/30/21. The reagents include but not are not limited to those listed below: Description Quantity GMP FLT-3L, 50 ug (Cat.# 001015-050) 8 GMP SCF, 50 ug (Cat.# 001018-050) 8 GMP TPO, 50 ug (Cat.# 001017-050) 8 The Vendor shall supply technical support for all reagents and their performance characteristics at no additional cost to the Government. Delivery Schedule These reagents will be shipped overnight delivery Monday through Thursday to: Katy Burkert CCE/CC/NIH Bldg 10, Room 3C720 9000 Rockville Pike Bethesda, MD 20892 -The contractor shall bear the cost of replacement for reagents found to be damaged or defective upon receipt by NIH or for incorrect or incomplete shipments. Government Responsibilities The CCE shall inspect shipments upon receipt and report any damage, defects or errors in shipment to the contractor. CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION This system is on site and has been validated for use on CC patients. It would be detrimental to the government to attempt to change systems and quite impossible as these instruments are proprietary and only distributed by CellGenix USA. With the continuation of using the same system will also help reduces the risk of a disruption in patient care. The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted as prescribed in FAR Part 10-Market Research. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, and the period of performance, the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by August 10th, 2021, 2:00 PM Eastern time and must reference solicitation number 21-011080. Responses may be submitted electronically to Mrs. Grace Wong-Darko, Contracting Specialist at Grace.Wong-Darko@nih.gov. Fax responses will not be accepted. "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency."

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:21-011080
  1. Pre-Solicitation

Formal solicitation typically follows within 30–60 days. (estimate)

  1. Pre-SolicitationCurrentJul 26, 2021

    CellGenix USA/ Various CellGenix cytokines for X-SCID.

    Notice 527654d21e7347bfbf716c7897da075d on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. Integrated DNA Technologies, Inc. is the sole owner, manufacturer, and distributor of the proprietary ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry, which has been utilized by the NHLBI Hematology Branch since 2019 to perform error-correcting sequencing (ECS) and is required to maintain scientific continuity, prevent technical batch effects across longitudinal patient cohorts, and ensure compatibility with the laboratory¿s established Archer Analysis bioinformatics pipeline. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing) and the small business size standard is 1,250 employees. This requirement is not set aside for small business.
-Combined Synopsis11/05/2026
1. Disclaimer THIS IS A SOURCES SOUGHT NOTICE ONLY. This notice is issued solely for information and market research planning purposes. It does not constitute a Request for Quotation (RFQ), Request for Proposal (RFP), or Invitation for Bids (IFB), nor does it restrict the Government to a particular acquisition approach. No contract or purchase order will be awarded from this announcement, and the Government will not reimburse respondents for any costs incurred in preparing a response. 2. Background and Purpose The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions,, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Section of Cell Cycle Regulation, has a requirement for a Brand-Name Lonza 4D-Nucleofector® System consisting of the following: 4D-Nucleofector Core Unit, Part No. AAF-1003B – Quantity (1) EA 4D-Nucleofector X Unit, Part No. AAF-1003X - Quantity (1) EA 3. One-year warranty extension for each unit. Or a functional domestic equivalent, to support ongoing NIH-funded research involving the genetic manipulation of mammalian cells. Because NICHD's ongoing studies rely on previously validated electroporation pulse-code workflows, experimental protocols, and Nucleocuvette™ consumables established on a prior-generation Lonza Nucleofector platform, the Lonza 4D-Nucleofector® System is the primary known platform capable of ensuring experimental reproducibility and data continuity without requiring costly and time-consuming protocol re-optimization or re-validation. The Office of Acquisitions is conducting market research to identify qualified vendors—including small businesses, authorized distributors, and domestic manufacturers—and specifically seeks market information to determine: 1. Authorized Lonza Sources: The availability of Lonza Walkersville, Inc. or authorized distributors/resellers (including small businesses, HUBZone, 8(a), SDVOSB, WOSB, and Small Disadvantaged Businesses under NAICS 334516) capable of supplying new Lonza equipment with full manufacturer-backed warranties. 2. Buy American Act (FAR Part 25) Compliance: The availability of any domestic end products manufactured in the United States capable of meeting all functional, warranty, training, and legacy workflow-continuity requirements outlined in Section 3 without requiring experimental re-validation. 3. Technical Requirements and Salient Characteristics To meet the Government's minimum requirements, the proposed system must satisfy all functional and technical specifications from the Statement of Work alongside the laboratory's workflow-continuity constraints: Core Control Unit: The system shall include a Lonza 4D-Nucleofector® Core Unit (or a domestic equivalent central control unit) capable of controlling and operating advanced electroporation-based transfection protocols. Small-Volume Transfection Module: The system shall include a Lonza 4D-Nucleofector® X Unit (or a domestic equivalent functional module) capable of processing small-volume samples (specifically ranging from 20 µL to 100 µL) and supporting transfection of primary cells and other difficult-to-transfect cell types. Nucleic Acid & Reagent Delivery: The system shall support delivery of plasmid DNA, RNA, siRNA, CRISPR/Cas9 reagents, and other nucleic acid-based materials into mammalian cells. Optimized Transfection Performance: The system shall provide optimized electroporation programs designed to maximize transfection efficiency while maintaining high post-transfection cell viability. Sensitive Cell Applications: The system shall support research applications involving primary cells, stem cells, immune cells, and other sensitive cell populations that are not efficiently transfected using conventional lipid-based methods. Software and Protocols: The system shall include manufacturer-provided software and protocols necessary for operation of the instrument. Warranty Coverage: The system shall include a minimum one-year manufacturer warranty and one-year warranty extension coverage for both the Core Unit and X Unit (two years total coverage). Warranty coverage shall begin upon Government acceptance of the equipment and continue in accordance with the manufacturer's warranty terms. Consumable & Legacy Protocol Continuity: If proposing Lonza equipment, the system shall be 100% compatible with commercially available Lonza Nucleofector® reagents, Nucleocuvette™ consumables, and existing pulse-code workflows previously developed and validated on a prior-generation Lonza Nucleofector platform. If proposing a domestic alternative, the vendor must demonstrate that its system and consumables achieve equivalent transfection efficiency and post-transfection cell viability across NICHD's existing mammalian cell workflows without requiring protocol re-optimization or experimental re-validation. Delivery, Installation, and Training: Equipment must be delivered to NIH Bethesda (Building 49) and installed, with on-site or virtual user training for up to five (5) NIH personnel completed within 30 days of installation (covering system operation, software functionality, routine maintenance, and basic troubleshooting). All delivery, installation, and training shall be completed within the 12-month period of performance from award. 4. Capability Statement Submission Instructions Interested organizations that believe they can meet all requirements outlined in Section 3 are invited to submit a tailored Capability Statement (no more than 5 pages) containing the following information: 1. Company Profile: Organization name, mailing address, primary Point of Contact (name, title, email, and telephone number), SAM.gov Unique Entity ID (UEI), and CAGE code. 2. Business Size & Socioeconomic Status: Business size under NAICS 334516 (1,000-employee size standard) and applicable socioeconomic designations (e.g., Small Business, Woman-Owned, Veteran-Owned, Service-Disabled Veteran-Owned, HUBZone, 8(a)). 3. Contract Vehicles: Identification of any existing federal contract vehicles held by the vendor through which this equipment can be ordered (e.g., GSA Multiple Award Schedule), or confirmation of open-market availability. 4. Country of Origin (COO): Explicit identification of the manufacturing country of origin for all proposed hardware components and confirmation of whether the system qualifies as a domestic end product under the Buy American Act (FAR Part 25). 5. Technical Capability & Authorization: Product brochures, technical specifications, and catalog numbers demonstrating compliance with every requirement in Section 3. If proposing Lonza equipment: Documentation confirming status as an Authorized Distributor/Reseller eligible to provide new equipment and manufacturer-backed warranties. If proposing a domestic alternative: Technical evidence proving equivalent transfection performance and workflow continuity with existing NICHD mammalian cell protocols without requiring experimental re-validation. 6. Rough Order of Magnitude (ROM) Pricing (Optional): Non-binding budgetary pricing estimate for market research purposes. 5. Place of Performance: NIH, 9000 Rockville Pike, Bethesda, MD 20892 6. Submission Deadline and Contact Information Please submit electronic Capability Statements in PDF or Microsoft Word format via email to Tina Robinson at robinsti@mail.nih.gov no later than November 18, 2026, at 11:00 AM EST. Telephone inquiries will not be accepted. Capability Statements must reference Notice Number 75N98027R00019. Email submissions and any questions must be sent to robinsti@mail.nih.gov and include Notice Number 75N98027R00019 in the subject line. Capability Statements and attachments will not be returned to the sender. This synopsis is for information and planning purposes only and shall not be construed as a commitment by the Government, nor will the Government pay for information solicited.
-Market Research11/18/2026
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Illumina, Inc. Acquisition Description: The purpose of this acquisition is to purchase two Illumina MiSeq i100 series instruments. These instruments will be used by the NIH HLA Laboratory to produce high resolution HLA typing results for the numerous transplant protocols supported by the laboratory. It will replace the current Illumina MiSeq instruments in the lab that were purchased in 2021 and 2022. The vendor will discontinue service on the current model of the MiSeq. New instruments are required to ensure time to validate these replacements before discontinuation of service. The total dollar value for this order is $139,100.52. The MiSeq is an integrated instrument that performs clonal amplification, genomic DNA sequencing, and data analysis with base calling, alignment, variant calling, and reporting in a single run. The MiSeq provides the Lab with the highest HLA typing results possible. The transplant protocols served by the HLA Lab require highest resolution possible to increase the chance of a successful transplant. The HLA Lab currently owns two MiSeq instruments, so the procedures and Quality Control assessments are in place. The order aims to replace the Illumina Miseq – s/n M07700 (property ID is 02223449) and s/n M08636 (property ID is 02268689) that were purchased in 2019 and 2022. Replacement is necessary to ensure proper performance of these instruments prior to discontinuation of service for the current model of the Illumina MiSeq instruments by the vendor. The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-27-000836) by 12:00 PM eastern standard time on 11/27/2026 to: valerie.gregorio@nih.gov. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
-Pre-Solicitation11/27/2026
FOOD AND DRUG ADMINISTRATION (FDA) Regulatory Support Services BPA SOURCES SOUGHT NOTICE (SSN) Description The U.S. Food and Drug Administration's (FDA), Office of Acquisitions and Grants Services (OAGS), is conducting market research for obtaining Regulatory Support Services. THIS IS A SOURCES SOUGHT NOTICE (SSN) ONLY. This SSN is being issued in accordance with Federal Acquisition Regulation (FAR) Part 10, Market Research. It is for information, planning and market research purposes only and is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. The Government reserves the right to contact any of the respondents after the submission deadline if additional information is required. The purpose of this SSN is to identify and gain knowledge of potential business sources and small business sources that are capable of providing the full range of services described in this SSN and the attached Draft Statement of Work (SOW). Responses to this SSN will be utilized for a potential solicitation for an anticipated stand-alone BPA for Regulatory Support Services Program. The anticipated period of performance for this contract is a Fiscal Year 2027 award with a base year, plus four (4) option years), with a potential 6-month extension of services pursuant to FAR 52.217-8. Requested Information Interested parties are highly encouraged to respond to this SSN by providing the following information in their response: Completed Vendor Feedback Form – See attached Vendor Feedback Form If applicable, tracked changes/comments on draft SOW in MS Word format – See attached Draft SOW Capability Statement Responses shall be submitted via email with the subject line "Sources Sought Notice - FDA SSN: CTP-2027-136871” to the Contracting Officer, Nicholas Bisher (Nicholas.Bisher@fda.hhs.gov), no later than 5:00pm (Eastern) on November 24, 2026. Attachments Vendor Feedback Form Draft Statement of Work
-Market Research11/24/2026
NOTICE OF INTENT – SOLE-SOURCE ACQUISITION Notice No.: 75N98027Q00078 The National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), intends to award a Firm-Fixed-Price Purchase Order to Vend Park for parking services at 6700B Rockledge Drive, Bethesda, Maryland. Description of the Requirement NHGRI requires parking spaces for its Federal employees and contractor personnel assigned to or supporting operations at 6700B Rockledge Drive. The requirement consists of access to 40 unreserved parking spaces and 6 reserved parking spaces for a Base Period and three (3) Option Periods. The parking spaces must be located within the 6700B Rockledge Drive complex to ensure employees and contractor personnel have convenient, reliable, and secure access to their assigned work location. The location of the parking facility is an essential requirement because personnel must be able to access the building through an appropriate and accessible route while meeting the facility's security and operational requirements. The contractor shall provide parking access cards to authorized personnel to facilitate access to the designated parking spaces throughout the period of performance. Justification for the Proposed Sole-Source Acquisition The Government intends to solicit from a single source pursuant to FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Vend Park is the proposed source because it owns and operates the only parking facility within the 6700B Rockledge Drive complex capable of meeting NHGRI's parking requirements. The Government's requirement is specific to this location due to the need to provide Federal employees and contractor personnel with parking that supports secure, accessible, and reliable access to their assigned work facility. The availability of parking within the complex is essential to the Government's operational needs. Parking facilities located elsewhere in the surrounding area do not provide an equivalent solution because they cannot meet the Government's requirement for parking within the complex and the associated access requirements for personnel reporting to 6700B Rockledge Drive. Requiring employees and contractor personnel to park at alternative facilities would not provide the same level of direct access to the building and would not satisfy the Government's location-specific security and accessibility requirements. Additionally, the requirement for both reserved and unreserved parking spaces, together with controlled access through parking access cards, must be met at the designated facility. Vend Park is the only identified source with the ability to provide the required parking spaces and associated access at this location. Based on the Government's market research, no other responsible source has been identified that can provide the required parking spaces within the 6700B Rockledge Drive complex while meeting the Government's security, accessibility, and operational requirements. Therefore, the Government has determined that Vend Park is the only known source capable of satisfying the agency's minimum needs and that no other available source can meet the requirement. Response Information This notice is not a request for competitive quotations or proposals. However, interested parties that believe they can satisfy the Government's requirements may submit a written capability statement demonstrating their ability to provide all required parking spaces and meet the specified location, security, accessibility, access, and operational requirements. Capability statements must specifically address the interested party's ability to provide 40 unreserved parking spaces and 6 reserved parking spaces within the 6700B Rockledge Drive complex, including the ability to provide the required parking access cards and meet the Government's location-specific requirements. The Government will review and evaluate all timely submitted capability statements to determine whether another responsible source is capable of meeting the Government's minimum requirements and whether a competitive acquisition is appropriate. The Government anticipates making an award approximately five (5) calendar days after the closing date of this notice, unless the Government determines that another responsible source is capable of satisfying the requirement. Capability statements must be submitted electronically to haunp@mail.nih.gov no later than 9:00 a.m. EDT on November 21, 2026. Please reference Notice No. 75N98027Q00078 in the subject line of the submission.
-Pre-Solicitation11/21/2026

Additional Details

Solicitation Number

21-011080

Archive Date

Aug 25, 2021

Place of Performance Country

DEU

Office Address

BETHESDA, MD, 20892